<DOC>
	<DOC>NCT01617447</DOC>
	<brief_summary>The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder</brief_summary>
	<brief_title>A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>The patient meets current DSMIVTR diagnostic criteria for Autistic Disorder (defined in DSMIVTR) and also demonstrates behaviors such as tantrums, aggression, selfinjurious behavior, or a combination of these problems. Inpatient or outpatient status Others The patient is currently diagnosed with another disorder on the autism spectrum in DSMIVTR, including Asperger's, Rett's Disorder, PDDNOS, Childhood Disintegrative Disorder, or FragileX Syndrome. Patients who fall under a contraindication listed in the ABILIFY package insert Others</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Autistic Disorder, children and adolescents</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>children and adolescents</keyword>
</DOC>